The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy
This study emphasizes the critical role of the ERRa-OAT1 axis in the pathogenesis of HN and non-HN CKD and highlights the potential of dapagliflozin in developing therapeutic strategies.